Abstract
Computational models based on recent maps of the red blood cell proteome suggest that mature erythrocytes may harbor targets for common drugs. This prediction is relevant to red blood cell storage in the blood bank, in which the impact of small molecule drugs or other xenometabolites deriving from dietary, iatrogenic or environmental exposures (“exposome”) may alter erythrocyte energy and redox metabolism and, in so doing, affect red cell storage quality and post-transfusion efficacy. To test this prediction, here we provide a comprehensive characterization of the blood donor exposome, including the detection of common prescription and off-the-counter drugs in 250 units donated by healthy volunteers from the REDS-III RBC Omics study. Based on high-throughput drug screenings of 1,366 FDA-approved drugs, we report a significant impact of ∼65% of the tested drugs on erythrocyte metabolism. Machine learning models built using metabolites as predictors were able to accurately predict drugs for several drug classes/targets (bisphosphonates, anticholinergics, calcium channel blockers, adrenergics, proton-pump inhibitors, antimetabolites, selective serotonin reuptake inhibitors, and mTOR) suggesting that these drugs have a direct, conserved, and significant impact on erythrocyte metabolism. We then focused on ranitidine – a common antiacid – as a representative drug with the potential to improve human erythrocyte storage quality and post-transfusion performances in mice. By combining tracing experiments with 1,2,3-13C3-glucose, proteome integral solubility alteration assays, genetic ablation of S1P synthesis capacity, in silico docking and 1D NMR, we show that ranitidine triggers metabolic mechanisms involving sphingosine 1-phosphate (S1P)-dependent modulation of erythrocyte glycolysis and/or direct binding to hemoglobin.
Key points
Blood donor exposomes include metabolites of environmental exposure, traces of common prescription or off-the-counter drugs;
65% of 1366 FDA- approved drug significantly affect RBC metabolism. Ranitidine significantly impacts glycolysis and S1P metabolism.
Competing Interest Statement
The authors declare that AD, TN and KCH are founders of Omix Technologies Inc and Altis Biosciencens LLC. AB and BOP are founders of Sinopia Biosciences Inc. JCZ and AD are consultants for Rubius Therapeutics. AD is an advisory board member for Hemanext Inc. and Forma Therapeutics Inc. All the other authors disclose no conflicts of interest relevant to this study.
Clinical Trial
BioLINCC Study: HLB02071919a
Funding Statement
Research reported in this publication was funded by the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III), which was supported by NHLBI contracts NHLBI HHSN2682011-00001I, -00002I, -00003I, -00004I, -00005I, -00006I, -00007I, -00008I, and -00009I, as well as funds from the the National Institute of General and Medical Sciences (RM1GM131968 to ADA and KCH), the Boettcher Webb-Waring Investigator Award (ADA), and R01HL146442 (ADA), R01HL149714 (ADA), R01HL148151 (ADA, JCZ), R21HL150032 (ADA), and T32 HL007171 (TN) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. . The authors would like to express their deep gratitude Dr. Simone Glynn of NHLBI for her support throughout this study, the RBC-Omics research staff at all participating blood centers and testing labs for their contribution to this project, and to all blood donors who agreed to participate in this study..
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Donor selection and recruitment for the RBC-Omics study under approved protocols (BioLINCC Study: HLB02071919a) were previously detailed in references 27-29 of this manuscript.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the raw data are provided in the Supplementary Table of this manuscript.